Erectile dysfunction

McMahon, Chris G

Topics

Abstract - Mechanism - Injection therapy - Transurethral alprostadil - Selective inhibitors - Guidelines - Conclusion - References - Authors' details

Correspondence:

1.
NIH Consensus Conference. Impotence, NIH Consensus DevelopmentPanel on Impotence. JAMA 1993; 270: 83-90.
2.
Pinnock CB, Stapleton AM, Marshall VR. Erectile dysfunction in thecommunity: a prevalence study. Med J Aust 1999; 171: 353-357.
3.
Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the UnitedStates: prevalence and predictors. JAMA 1999; 281: 537-544.
4.
Linet OI, Ogrinc FG. Efficacy and safety of intra-cavernosalalprostadil in men with erectile dysfunction. The Alprostadil StudyGroup. N Engl J Med. 1996; 334: 873-877.
5.
National Health and Medical Research Council. A guide to thedevelopment, implementation and evaluation of clinical practiceguidelines. Canberra: NHMRC, AusInfo, 1999.
6.
Poch G, Kukovetz WR. Papaverine-induced inhibition ofphosphodiesterase activity in various mammalian tissues. LifeSci 1971; 10: 133-144.
7.
Hakenberg O, Wetterauer U, Koppermann U, Liffimann R. Systemicpharmacokinetics of papaverine and phentolamine: Comparison ofintravenous and intracorporal application. Int J ImpotenceRes 1990; 2 (Suppl 2): 247-248.
8.
Porst H. The rationale for prostaglandin E1 in erectile failure: asurvey of world-wide experience. J Urol 1996; 155: 802-815.
9.
De Rose AF, Oppezzi GF, Scotto S. [Local complications ofpapaverine-induced erection: follow-up at 7 years] [Article inItalian]. Arch Ital Urol Androl 1993; 65: 289-293.
10.
Brown LS, Christopher AH, Koehler M, et al. Hepatotoxicityrelated to intracorporal pharmacotherapy with papaverine.Urology 1998; 52: 844-847.
11.
Paoletti R. Biochemistry and pharmacology of prostaglandin E1:introductory remarks. In: Sinzinger H, Rogatti W, editors.Prostaglandin E1 in atherosclerosis. New York: Springer-Verlag,1986: 3-7.
12.
Chen RN, Lakin MM, Montague DK, Ausmundson S. Penile scarring withintracorporal injection therapy using prostaglandin E1: a riskfactor analysis. J Urol 1996; 155: 138-140.
13.
Chew KK, Stuckey BG, Earle CM, et al. Penile fibrosis inintracavernosal prostaglandin E1 injection therapy for erectiledysfunction. Int J Impotence Res 1997; 9: 225-229;discussion, 229-230.
14.
Moreland RB, Traish A, McMillin MA, et al. PGE1 suppresses theinduction of collagen synthesis by transforming growth factor-beta1 in human corpus cavernosum smooth muscle. J Urol 1995; 153:826-834.
15.
Padma-Nathan H. The efficacy and synergy of polypharmacotherapyin primary and salvage therapy of vasculogenic erectile failure.Int J Impotence Res 1990; 2: 257-258.
16.
McMahon CG. Comparison of the response to the intracavernosalinjection of a combination of papaverine and phentolamine,prostaglandin E1 alone and a combination of all three in themanagement of impotence. Int J Impotence Res 1991; 3:133-142.
17.
Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of menwith erectile dysfunction with transurethral alprostadil.Medicated Urethral System for Erection (MUSE) Study Group. N EnglJ Med 1997; 336: 1-7.
18.
Fulgham PF, Cochran JS, Denman JL, et al. Disappointing initialresults with transurethral alprostadil for erectile dysfunction ina urology practice setting. J Urol 1998; 160: 2041-2046.
19.
Porst H. Transurethral alprostadil with MUSE (medicatedurethral system for erection) vs intracorporal alprostadil -- acomparative study in 103 patients with erectile dysfunction. IntJ Impotence Res 1997; 9: 187-192.
20.
Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in thetreatment of erectile dysfunction. Sildenafil Study Group. NEngl J Med 1998; 338: 1397-1404.
21.
Dinsmore WW, Hodges M, Hargreaves C, et al. Sildenafil citrate(Viagra) in erectile dysfunction: near normalization in men withbroad-spectrum erectile dysfunction compared with age-matchedhealthy control subjects. Urology 1999; 53: 800-805.
22.
Jarow JP, Burnett AL, Geringer AM. Clinical efficacy ofsildenafil citrate based on etiology and response to priortreatment. J Urol 1999; 162: 722-725.
23.
McMahon CG, Samali R, Johnston HM. Treatment of IntracorporalInjection Non-Responders with Sildenafil Alone or in Combinationwith Polyagent Intracorporal Injections. J Urol 1999; 162:1992-1997.
24.
Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expertconsensus document. Use of sildenafil (Viagra) in patients withcardiovascular disease. American College of Cardiology/AmericanHeart Association. J Am Coll Cardiol 1999; 33: 273-282.
25.
Always use alprostadil monotherapy as first-line ICI treatment.
26.
Use lowest possible effective dose.
27.
Inform patient of the risk of prolonged erection and the procedure to be followed if the penis is still rigid, as follows:

Online responses are no longer available. Please refer to our instructions for authors page for more information.